Abstract

Pathogen nucleic acid detection exhibits faster turnaround times and higher sensitivity compared with blood culture. When antibiotics are present, blood cultures experience higher false-negative rates. In contrast, nucleic acid tests may detect pathogens irrespective of antimicrobial therapy. Thus, future point-of-care nucleic acid-based detection devices could play a role in revolutionizing pathogen detection in critically ill patients. To properly optimize clinical use, pathogen nucleic acid tests should have the capacity to quantitate pathogen DNA, be miniaturized with simplified preanalytical and postanalytical processing components, and reduce net operating costs or provide clear-cut clinical outcome benefits. These 3 elements will foster a new generation of nucleic acid tests for use at the point of need and facilitate a paradigm shift to point-of-care pathogen detection with evidence-based treatment and real-time quantitative monitoring of patients with sepsis.

Original languageEnglish (US)
Pages (from-to)107-110
Number of pages4
JournalPoint of Care
Volume7
Issue number3
DOIs
StatePublished - Sep 2008

Fingerprint

Point-of-Care Systems
Nucleic Acids
Sepsis
Physiologic Monitoring
Critical Illness
Anti-Bacterial Agents
Costs and Cost Analysis
Equipment and Supplies
DNA
Therapeutics

Keywords

  • Analytical sensitivity
  • Blood culture
  • Cost-effectiveness
  • Loop-mediated isothermal amplification
  • Low resource
  • Point of care
  • Polymerase chain reaction, quantitative nucleic acid testing

ASJC Scopus subject areas

  • Nursing(all)

Cite this

@article{f7d1f140e00b4467b9548beacded5efa,
title = "Quantitative point-of-care pathogen detection in septicemia",
abstract = "Pathogen nucleic acid detection exhibits faster turnaround times and higher sensitivity compared with blood culture. When antibiotics are present, blood cultures experience higher false-negative rates. In contrast, nucleic acid tests may detect pathogens irrespective of antimicrobial therapy. Thus, future point-of-care nucleic acid-based detection devices could play a role in revolutionizing pathogen detection in critically ill patients. To properly optimize clinical use, pathogen nucleic acid tests should have the capacity to quantitate pathogen DNA, be miniaturized with simplified preanalytical and postanalytical processing components, and reduce net operating costs or provide clear-cut clinical outcome benefits. These 3 elements will foster a new generation of nucleic acid tests for use at the point of need and facilitate a paradigm shift to point-of-care pathogen detection with evidence-based treatment and real-time quantitative monitoring of patients with sepsis.",
keywords = "Analytical sensitivity, Blood culture, Cost-effectiveness, Loop-mediated isothermal amplification, Low resource, Point of care, Polymerase chain reaction, quantitative nucleic acid testing",
author = "Nam Tran and Wisner, {David H} and Albertson, {Timothy E} and Cohen, {Stuart H} and Greenhalgh, {David G} and Galante, {Joseph M} and Phan, {Ho H} and Kost, {Gerald J}",
year = "2008",
month = "9",
doi = "10.1097/POC.0b013e318182994b",
language = "English (US)",
volume = "7",
pages = "107--110",
journal = "Point of Care",
issn = "1533-029X",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Quantitative point-of-care pathogen detection in septicemia

AU - Tran, Nam

AU - Wisner, David H

AU - Albertson, Timothy E

AU - Cohen, Stuart H

AU - Greenhalgh, David G

AU - Galante, Joseph M

AU - Phan, Ho H

AU - Kost, Gerald J

PY - 2008/9

Y1 - 2008/9

N2 - Pathogen nucleic acid detection exhibits faster turnaround times and higher sensitivity compared with blood culture. When antibiotics are present, blood cultures experience higher false-negative rates. In contrast, nucleic acid tests may detect pathogens irrespective of antimicrobial therapy. Thus, future point-of-care nucleic acid-based detection devices could play a role in revolutionizing pathogen detection in critically ill patients. To properly optimize clinical use, pathogen nucleic acid tests should have the capacity to quantitate pathogen DNA, be miniaturized with simplified preanalytical and postanalytical processing components, and reduce net operating costs or provide clear-cut clinical outcome benefits. These 3 elements will foster a new generation of nucleic acid tests for use at the point of need and facilitate a paradigm shift to point-of-care pathogen detection with evidence-based treatment and real-time quantitative monitoring of patients with sepsis.

AB - Pathogen nucleic acid detection exhibits faster turnaround times and higher sensitivity compared with blood culture. When antibiotics are present, blood cultures experience higher false-negative rates. In contrast, nucleic acid tests may detect pathogens irrespective of antimicrobial therapy. Thus, future point-of-care nucleic acid-based detection devices could play a role in revolutionizing pathogen detection in critically ill patients. To properly optimize clinical use, pathogen nucleic acid tests should have the capacity to quantitate pathogen DNA, be miniaturized with simplified preanalytical and postanalytical processing components, and reduce net operating costs or provide clear-cut clinical outcome benefits. These 3 elements will foster a new generation of nucleic acid tests for use at the point of need and facilitate a paradigm shift to point-of-care pathogen detection with evidence-based treatment and real-time quantitative monitoring of patients with sepsis.

KW - Analytical sensitivity

KW - Blood culture

KW - Cost-effectiveness

KW - Loop-mediated isothermal amplification

KW - Low resource

KW - Point of care

KW - Polymerase chain reaction, quantitative nucleic acid testing

UR - http://www.scopus.com/inward/record.url?scp=67650161911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650161911&partnerID=8YFLogxK

U2 - 10.1097/POC.0b013e318182994b

DO - 10.1097/POC.0b013e318182994b

M3 - Article

AN - SCOPUS:67650161911

VL - 7

SP - 107

EP - 110

JO - Point of Care

JF - Point of Care

SN - 1533-029X

IS - 3

ER -